Jubilant Pharmova enterprise value

·Pharma & HealthChart ›
MultiplesEnterprise valuePer share
Share price at each year-end
Tap a line for its trendCurrentlast 12MFY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023FY22 and earlierAlpha Plus
14,947————
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
1,2671,2671,0889561,014
2.82.8−16.3−12.8−7.5
3,2203,2202,4373,4143,410
16,902————
1,9521,9521,3492,4582,396
₹1,069.75————
10,31510,3158,6768,8358,802
31.2%31.2%28.1%38.6%38.7%
0.19×————
1.96×————
13.87×————
22.58×————
Reference items — trailing FY values
8,6088,2807,2356,7036,282
1,2181,2601,174901776
749819805519222
—1,2271,072971661
−222−222−43.573.6−154
—−306−78.2−72.6−294
—1,4491,116898814
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

JUBLPHARMA₹946.00

Jubilant Pharmova Ltd.

· Pharma & Health
₹ CrorePeersGLANDPPLPHARMAKIMSINDGNONESOURCEGRANULESPFIZERPOLYMEDMcap ₹14,947 Cr
HighlightsEnterprise ValueMultiplesPer ShareAnnuals · FY-end closes
In ₹ Crore except Per Share
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Current/LTM
TTM · last close
Market Capitalization————14,946.8
- Cash, Equiv & ST Investments1,013.9956.41,088.31,267.11,267.1
+ Minority Interest-7.5-12.8-16.32.82.8
+ Total Debt3,410.13,414.12,436.93,219.53,219.5
Enterprise Value————16,902.0
Net Debt (memo)2,396.22,457.71,348.61,952.41,952.4
EV per Share————1,069.75
Total Capital8,801.98,835.28,675.510,315.110,315.1
Total Debt/Total Capital38.7438.6428.0931.2131.21
Total Debt/EV————0.19
EV/Sales————1.96
EV/EBITDA————13.87
EV/EBIT————22.58
Reference Items — Trailing FY Values
Sales6,281.76,702.97,234.58,279.68,608.3
EBITDA776.3900.81,173.71,259.81,218.2
EBIT222.2518.9805.1819.4748.6
Operating Cash Flow660.7971.31,072.11,226.8—
Free Cash Flow-153.873.6-43.5-222.3-222.3
FCFF (free cash flow to the firm)-294.3-72.6-78.2-306.3—
Capital Expenditure814.5897.71,115.61,449.1—
Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.